Issue Date: June 27, 2016
Teva continues portfolio divestment
Teva Pharmaceutical Industries continues to divest products to satisfy antitrust regulators assessing its planned acquisition of Allergan’s generic drug business. Impax Laboratories will pay $586 million for 15 marketed generics plus the rights to products not yet launched and to the pending Abbreviated New Drug Application (ANDA) for the generic equivalent of Concerta, a product on which the two companies collaborated. Sagent Pharmaceuticals, meanwhile, will pay $40 million for five ANDAs pending in the U.S. Earlier this month, Teva sold a raft of ANDAs to Dr. Reddy’s Laboratories.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society